Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186611 | 0.89 | MEN1 (0.41) | USP2SMN1; SMN2CYP4F2CYP4A11MEN1 | |
| SCHEMBL963907 | 0.89 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL7309006 | 0.87 | USP2 (0.43) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL606159 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL20565162 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL415499 | 0.86 | MEN1 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11MEN1 | |
| SCHEMBL26103503 | 0.86 | SMN1; SMN2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL390461 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL4129353 | 0.86 | PKM (0.48) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL3634007 | 0.86 | SMN1; SMN2 (0.37) | USP2SMN1; SMN2CYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251620-B1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| EP-4251620-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| CN-114787167-A | Compounds and compositions for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| CN-1305470-A | Amidine compounds | JAPAN TOBACCO INC (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-0983257-A4 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0983257-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | Monsanto Company (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998039315-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | USP2 3031/4885SMN1; SMN2 4289/4885CYP4F2 4128/4885 |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | USP2 4860/4885SMN1; SMN2 693/4885CYP4F2 223/4885 |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | USP2 3470/4885SMN1; SMN2 4528/4885CYP4F2 2491/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | USP2 4860/4885SMN1; SMN2 693/4885CYP4F2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.